Opus Genetics (IRD) Projected to Post Quarterly Earnings on Friday

Opus Genetics (NASDAQ:IRD) is expected to be announcing its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $11.10 million for the quarter.

Opus Genetics Stock Performance

IRD opened at $0.93 on Thursday. The firm has a market capitalization of $29.38 million, a PE ratio of -0.85 and a beta of 0.28. Opus Genetics has a twelve month low of $0.81 and a twelve month high of $1.56. The business’s fifty day moving average price is $1.14.

Insiders Place Their Bets

In other Opus Genetics news, CEO George Magrath bought 100,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were acquired at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the purchase, the chief executive officer now owns 599,150 shares in the company, valued at approximately $587,167. This trade represents a 20.03 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Opus Genetics in a research note on Wednesday, February 19th.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.